CytomX: PROBODY® Conditional Activation Technology Designed to Expand ADC Target Landscape
Time: 4:00 pm
day: Day One - PM
Details:
- Sharing industry-leading PROBODY® masking technology which leverages elevated protease activity in the tumor microenvironment and is designed to increase the therapeutic index by reducing on-target off-tumor toxicities while potentially maintaining potent anti-tumor efficacy
- Discussing PROBODY® platform with proof of mechanism: stability in circulation, intratumoral activation and single agent activity across multiple indications
- Outlining how PROBODY® technology is designed to unlock EpCAM as a systemic ADC target (CX-2051, PROBODY® EpCAM-Topo1 ADC currently in Ph1) and may be applied to other ADC targets with low or negative therapeutic index